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Hormonal Regulation of 
Cutaneous Melanoma: A Brief 
Review of In Vivo and In Vitro 
Studies and Its Clinical Implication
Pandurangan Ramaraj
Abstract
Skin is an endocrine organ. Skin produces various hypothalamic, pituitary, adrenal 
and sex steroid hormones. This raises the question whether skin cancer melanoma is 
a hormone dependent cancer. But, a review of in-vivo and in-vitro studies suggested 
that melanoma could be a hormone responsive cancer or hormone sensitive cancer. In 
fact, previous clinical study showed that menstruating females were better protected 
in melanoma than post-menopausal women and men of any age. However, the study 
did not show any direct effect of steroid hormone on melanoma cells. Our in-vitro 
study showed that progesterone, a female sex hormone significantly inhibited human 
melanoma (BLM) cell growth. Progesterone inhibitory effect on other melanoma 
cell lines was also reported by Fang et al., Moroni et al. and Kanda and Watanbe. So, 
it was hypothesized that progesterone could be protecting menstruating females in 
melanoma. Our further research showed that progesterone action was mediated by a 
specific suppression of pro-inflammatory cytokine IL-8. Several in-vivo and in-vitro 
studies showed the importance of IL-8 in the regulation of melanoma growth. Hence, 
IL-8 could be considered as a potential target for melanoma treatment.
Keywords: skin, steroid hormones, melanoma, in vivo and in vitro studies, 
progesterone, IL-8
1. Introduction
The skin is not only a target organ for sex hormones [1] but also an endocrine 
organ. The skin produces sex hormones, viz., androgens, estrogen, and progestins, 
which function locally [2, 3]. Weak androgens such as dehydroepiandrosterone 
(DHEA), DHEA sulfate (DHEAS), and androstenedione are converted to more 
potent testosterone and 5-α-dihydrotestosterone in the skin [4]. In addition, the 
skin has all the elements of neuroendocrine axis with the expression of corticotro-
phin-releasing hormone (CRH), pro-opiomelanocortin (POMC), and associated 
peptides ACTH, α-melanocyte-stimulating hormone (MSH), β-endorphin, and 
corticotrophin-releasing hormone receptor-1 [5, 6]. The presence of receptor and 
the peptides in the same cell suggests auto-, para-, and intracrine functions of these 
axes. The skin has nervous and hormonal pathways not only to regulate itself but 
also to regulate systemic homeostasis. Imbalances in hormones affect skin texture 
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and cause skin diseases such as rosacea, atopic dermatitis, and psoriasis [7, 8]. 
Melanoma is one such fatal disorder or disease of the skin [9], which is believed to 
be caused by UV rays [10]. According to the Cancer Society Report, melanoma is 
on the rise. In 2018 alone 91,720 new cases would be diagnosed in the United States 
with an estimated 9000 deaths in the United States alone [11]. It has been shown 
that sex steroids are essential for a healthy skin. Since melanoma is a serious skin 
disease, the question, whether melanoma is a hormone dependent cancer or not is 
relevant here. Literature survey showed possible dependence of melanoma on endo-
crine influences [12–14]. Several in vivo and in vitro studies showed the involve-
ment of steroids in the regulation of melanoma growth.
2. Brief review of in vivo studies
2.1 Animal studies
Animal studies showed the involvement of sex steroid hormones in the regula-
tion of melanoma growth, and there were also differences in the regulation of 
growth between male and female mice:
a. In one study, estrogen receptor-positive human melanoma cells grew more 
slowly in female than in male mice [15].
b. Female survival benefit with metastatic melanoma was observed, when 
melanoma cells produced liver metastases preferentially in male compared to 
female mice [16].
c. In another study, dihydrotestosterone was shown to stimulate proliferation, 
whereas anti-androgen receptor hydroxyflutamide [17] showed anticancer 
action in a male mouse transplanted with melanoma.
In the following two studies, it was shown that male mice were more prone to 
cancer than female mice:
d. When induced with carcinogen [18].
e. When exposed to UV-B [19].
2.2 Clinical studies
Overall survival outcome for young women (45 years of age and under) was 
far superior to older women (55 years of age and older) and men of any age group 
[20]. A 22% survival advantage and 17% 5 year disease-free interval advantage were 
observed in females [21]. In addition, women were found to survive longer than 
men after the development of stage III disease [22]. Clinical studies also suggested 
the involvement of hormones in the regulation of melanoma growth. So, clinical 
studies underlined the involvement of female sex steroid hormones in protecting 
menstruating females in melanoma. But, these clinical studies did not identify 
the exact female hormone involved in the protection. In addition, there was no 
statistically significant difference observed in the survival rates between controls 
and women diagnosed with melanoma stage I or stage II during pregnancy [23–25]. 
Data also showed no correlation between melanoma and oral contraceptives 
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[26, 27]. Available data suggested no connection between exogenous hormones and 
the risk for malignant melanoma [28, 29].
3. Brief review of in vitro studies
The following in vitro studies showed inhibitory effect of steroid hormones on a vari-
ety of melanoma cell lines, suggesting melanoma could be a hormone-sensitive cancer:
a. 2-Methoxyestradiol (2-ME), an estrogenic metabolite, inhibited all tested 
melanoma cell line growth, without affecting the growth of non-tumorigenic 
cells [30].
b. Kanda and Watanbe showed that 17-β-estradiol, progesterone, and dihydrotes-
tosterone inhibited melanoma cell growth in a receptor-dependent manner by 
suppressing IL-8 transcription [31].
c. Amelanotic strain cells grew faster in vivo in female hamsters [32], whereas 
testosterone inhibited the cell growth in vitro.
d. Glucocorticoids also showed their effect on melanoma cell growth in a  
receptor-dependent manner [33].
e. Another in vitro study showed that melatonin at physiological concentra-
tions (1 nM to 10 pM) inhibited metastatic mouse melanoma (B16BL6) cell 
growth [34].
4. In vitro studies from our lab
Our lab in vitro studies showed involvement of progesterone in the regulation of 
mouse and human melanoma cell growth.
4.1  Dose-response studies of progesterone with mouse (B16F10) and human 
melanoma (BLM) cell line
Initially four sex steroids, viz., dehydroepiandrosterone (DHEA), androstene-
dione (AD), testosterone (T), and progesterone (P4), were checked for their effect 
on mouse melanoma (B16F10) cell growth [35]. Though all four steroids showed a 
dose-dependent effect, progesterone showed a significant effect on the inhibition of 
mouse melanoma cell growth (Figure 1). As the initial study was carried out at high 
concentrations (100, 150, and 200 μM), dose-response study was carried out to rule 
out toxic effect of high concentrations of steroids on melanoma cell growth inhibi-
tion. Mouse (B16F10) and human melanoma (BLM) cells showed a dose-dependent 
cell growth inhibition [35, 36], suggesting the inhibition was not due to toxic effect 
at high concentration of steroids (Figure 1).
4.2 Mechanism of inhibition of human melanoma (BLM) cell growth
After having ruled out necrosis and apoptosis as the cause of cell growth inhibition, it 
was found out that autophagy was the mechanism of cell growth inhibition (Figure 2), 
using a known inducer of autophagy (spermidine) in a control experiment [36].
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Figure 2. 
Mechanism of cell death by progesterone. After having ruled out necrosis and apoptosis, autophagy was 
checked by adding 3-methyladenine (3-MA). Control experiment with 100 μM of spermidine-induced 
autophagy was partially rescued by the addition of 2 mM of 3-methyladenine (as 3-MA inhibited the 
assembly of autophagosome formation [37, 38]). Similar partial rescue of cell growth was observed at various 
concentrations of progesterone, suggesting the mechanism of inhibition of cell growth was due to autophagy.
Figure 1. 
Dose-response studies of progesterone with mouse (B16F10) and human melanoma (BLM) cell lines. Initially 
dehydroepiandrosterone, androstenedione, testosterone, and progesterone were tested for their effects on mouse 
melanoma (B16F10) cell growth by MTT assay. Progesterone, a female sex hormone, showed significant 
inhibition at 150 and 200 μM concentrations. As steroids were tested initially at high concentrations (100, 150, 
and 200 μM), dose-response study was carried out to rule out toxic effect of steroid at high concentrations. 
Dose-response studies of mouse (B16F10) and human melanoma (BLM) cell lines showed a sigmoidal dose-
response curve, ruling out toxic effect of steroids due to high concentrations.
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4.3  Effect of progesterone on adhesion and migration functions of human 
melanoma cells
Effects on adhesion and migration functions were checked after 48 h incubation 
of human melanoma cells with progesterone. Progesterone at 100 μM concentration 
partially inhibited adhesion function (Figure 3). Similarly, progesterone (50 μM) 
treatment significantly decreased migration function of human melanoma cells 
(Figure 3). This study indicated that progesterone treatment decreased adhesion 
and migration functions [39] which were essential for metastasis of melanoma.
5. In vitro studies from other labs
In addition, in vitro inhibition of melanoma cell growth by progesterone was 
also shown by other labs:
a. Fang et al. showed inhibition of human melanoma cell lines (A375, A875) by 
progesterone and RU-486, which were not mediated through progesterone 
receptor [40].
b. Moroni et al. repeated the studies with A375 cell line and used progesterone 
concentration up to 1000 μM, which also showed inhibition of human mela-
noma cell growth [41].
c. Kanda and Watanbe used progesterone along with dihydrotestosterone and 
estrogen and showed that all the three steroids inhibited human melanoma 
cell growth by decreasing IL-8 transcription [31].
6. Biochemical basis of progesterone action
Further research [42] involving ELISArray of supernatants of the cells treated 
with progesterone along with untreated control cells showed that progesterone action 
was mediated by a specific suppression pro-inflammatory cytokine IL8 (Figure 4).
Figure 3. 
In vitro adhesion and migration functions of human melanoma cell line. Human melanoma cells were treated 
with progesterone at 100 μM for 48 h in petri dish. After 48 h, both control and progesterone-treated cells were 
harvested, and adhesion assay was carried out as per the protocol in Ref. [28]. For migration assay, control and 
progesterone (50 μM)-treated cells were harvested after 48 h of treatment. Adhesion experiment showed partial 
inhibition of adhesion in progesterone-treated cells compared to untreated control cells. Similarly, progesterone-
treated cells showed a significant decrease in migration function in progesterone-treated cells compared to 
untreated control cells.
Cutaneous Melanoma
6
6.1 Involvement of IL-8 in melanoma growth
In vivo and in vitro studies from other labs showed the involvement of IL-8 in 
melanoma growth:
1. IL-8 cytokine produced in vitro was an essential autocrine growth factor for 
melanoma cells [43].
2. Expression of IL-8 in human melanoma cells upregulated the activity of matrix 
metalloproteinase (MMP) and increased tumor growth and metastasis [44].
3. Expression of IL-8 correlated with metastatic potential of human melanoma 
cell in nude mouse [45].
7. Summary
In vivo and in vitro studies showed the inhibition of melanoma growth by vari-
ous hormones. This inhibition of cell growth by various hormones suggested that 
melanoma could be a hormone-responsive cancer, where hormones were essential 
for survival in melanoma. This was supported by the clinical studies carried out 
in the 1950s and 1960s. One clinical study reported that menstruating females 
were better protected in melanoma than postmenopausal women and men of any 
age [20]. But, the study did not correlate with steroid status of females. Literature 
showed that progesterone level peaked in menstruating females between 1000 and 
1500 ng/dl, whereas progesterone level ranged between 20 and 100 ng/dl  
in postmenopausal women [46]. Our research also showed that progesterone 
inhibited human melanoma (BLM) cell growth in vitro significantly. In addition, 
progesterone inhibitory action was also shown by Fang et al., Moroni et al., and 
Kanda and Watanbe. So, it was hypothesized that progesterone could be protecting 
menstruating females. Recently, it was shown that the protective function of pro-
gesterone was mediated by a specific suppression of pro-inflammatory cytokine 
IL-8. Various in vitro and in vivo studies already showed the importance of IL-8 in 
melanoma cell growth.
Figure 4. 
Biochemical basis of progesterone action. An ELISArray, containing pro- and anti-inflammatory cytokine 
antibodies coated in different wells, showed a specific suppression of IL-8 cytokine alone in the supernatant of 
cells treated with progesterone (50 μM) compared to untreated control cell supernatant.
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8. Conclusion
Several studies showed the involvement of progesterone in the regulation of 
in vitro melanoma cell growth and also in the regulation of in vivo melanoma 
growth. Further in vitro research showed that the progesterone inhibitory action 
was mediated by a specific suppression of pro-inflammatory cytokine IL-8. The 
connection between IL-8 and melanoma growth was already established by other 
investigators. This brought IL-8 into focus in melanoma and suggested that IL-8 
could be considered as a potential target for melanoma treatment.
Author details
Pandurangan Ramaraj
Department of Biochemistry, Kirksville College of Osteopathic Medicine, A.T. Still 
University of Health Sciences, Kirksville, MO, USA
*Address all correspondence to: pramaraj@atsu.edu
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
8Cutaneous Melanoma
[1] Zouboulis CC. The human skin as a 
hormone target and an endocrine gland. 
Hormones. 2004;3(1):9-26
[2] Zouboulis CC. Human skin: An 
independent peripheral endocrine organ. 
Hormone Research. 2000;54:230-242
[3] Zouboulis CC, Chen WC,  
Thornton MJ, Qin K, Rosenfield R.  
Sexual hormones in human skin. 
Hormone and Metabolic Research. 
2007;39(2):85-95
[4] Labrie F. DHEA and its 
transformation into androgens 
and estrogens in peripheral target 
tissues: Intracrinology. Frontiers in 
Neuroendocrinology. 2001;22(3):185-212
[5] Slominski A, Wortsman J.  
Neuroendocrinology of the skin. 
Endocrine Reviews. 2000;21(5):457-487
[6] Slominski A, Wortsman J. Self-
regulated endocrine systems in the 
skin. Minerva Endocrinologica. 
2003;28(2):135-143
[7] Slominski A, Zbytek B, Nikolakis G, 
Manna PR, Skobowiat C, Zmijewski M,  
et al. Steroidogenesis in the skin: 
Implications for local immune 
functions. The Journal of Steroid 
Biochemistry and Molecular Biology. 
2013;137:107-123. DOI: 10.1016/j.
jsbmb.2013.02.006. Epub 2013 Feb19
[8] Nikolakis G, Stratakis CA,  
Kanaki T, Slominski A, Zouboulis 
CC. Skin steroidogenesis in health 
and disease. Reviews in Endocrine & 
Metabolic Disorders. 2016;17(3):247-258
[9] Gray-Schopfer V, Wellbrock C, Marais 
R. Melanoma biology and new targeted 
therapy. Nature. 2007;445:851-857
[10] Rass K, Reicharth J. UV damage and 
DNA repair in malignant melanoma 
and non-melanoma skin cancer. 
Advances in Experimental Medicine 
and Biology. 2008;624:162-178. DOI: 
10.1007/978-0-387-77574-6_13
[11] Available from: http://seer.cancer.
gov/statfacts/html/melan.html
[12] Sadoff L, Winkley J, Tyson S. Is 
malignant melanoma an endocrine-
dependent tumor? Oncology. 
1973;27:244-257
[13] Gupta A, Driscoll MS. Do hormones 
influence melanoma? Facts and 
controversies. Clinics in Dermatology. 
2010;28(3):287-292
[14] De Giorgi V, Gori A, Alfaioli B,  
Papi F, Grazzini M, Rossari S, 
et al. Influence of sex hormones 
on melanoma. Journal of Clinical 
Oncology. 2011;29(4):e94-e95
[15] Feucht KA, Walker MJ, Das 
Gupta TK, Beattie CW. Effect of 
17-β-oestradiol on the growth of 
estrogen receptor positive human 
melanoma in vitro and in athymic mice. 
Cancer Research. 1988;48:7093-7101
[16] Ladanyi A, Timar J, Bocsi J, Towari J, 
Lapis K. Sex-dependent liver metastasis 
of human melanoma lines in SCID mice. 
Melanoma Research. 1995;5:83-86
[17] Morvillo V, Luthy IA, Bravo AI, 
Capurro MI, Donaldson M, Quintans 
C, et al. Atypical androgen receptor 
in the human melanoma cell line 
IIB-MEL-J. Pigment Cell Research. 
1995;8(3):135-141
[18] Simanainen U, Ryan T, Li D, Suarez 
FG, Gao YR, Watson G, et al. Androgen 
receptor actions modify skin structure 
and chemical carcinogen-induced skin 
cancer susceptibility in mice. Hormones 
and Cancer. 2015;6:45-53
[19] Thomas-Ahner JM, Wulff BC,  
Tober KL, Kusewitt DF, Riggenbach JA,  
References
9Hormonal Regulation of Cutaneous Melanoma: A Brief Review of In Vivo and In Vitro Studies…
DOI: http://dx.doi.org/10.5772/intechopen.86593
Oberyszyn TM. Gender differences 
in UV-B induced skin carcinogenesis, 
inflammation and DNA damage. 
Cancer Research. 2007;67(7): 
3468-3474. DOI: 10.1158/0008-5472.
CAN-06-3798
[20] Kemeny MM, Busch E, Stewart AK, 
Mench HR. Superior survival of young 
women with malignant melanoma. 
American Journal of Surgery. 
1988;175:437-444
[21] Miller JG, Neil SM. Gender 
and cutaneous melanoma. The 
British Journal of Dermatology. 
1997;136:657-665
[22] Rumke P, Kleeberg UR, Mackie RM, 
Lejeune FJ, Planting AS, Brocker EB, 
et al. Tamoxifen as a single agent for 
advanced melanoma in postmenopausal 
women. A phase II study of the 
EORTC malignant melanoma 
cooperative group. Melanoma Research. 
1992;2:153-156
[23] Smith MA, Fine JA, Barnhill RL, 
Berwick M. Hormonal and reproductive 
influences and risk of melanoma 
in women. International Journal of 
Epidemiology. 1998;27(5):751-757
[24] Miller E, Barnea Y, Gur E, 
Leshem D, Karin E, Weiss J, et al. 
Malignant melanoma and pregnancy: 
Second thoughts. Journal of Plastic, 
Reconstructive & Aesthetic Surgery. 
2010;63(7):1163-1168. DOI: 10.1016/j.
bjps.2009.05.050
[25] Schaepkens van Riempst J, 
Abdou M, Schertenleib P. Melanoma: 
A protective role of pregnancy? A 
case report and review of literature. 
(Article in French). Annales de 
Chirurgie Plastique et Esthétique. 
2011;56(1):43-48
[26] Leslie KK, Espey E. Oral 
contraceptives and skin cancer: Is there 
a link? American Journal of Clinical 
Dermatology. 2005;6(6):349-355
[27] Hannaford PC, Villard-
Mackintosh L, Vessey MP, Kay 
CR. Oral contraceptives and malignant 
melanoma. British Journal of Cancer. 
1991;63(3):430-433
[28] Durvasula R, Ahmed SM,  
Vashisht A, Studd JW. Hormone 
replacement therapy and malignant 
melanoma: To prescribe or 
not to prescribe? Climacteric. 
2002;5(2):197-200
[29] Tang JY, Spaunhurst KM, 
Chlebowski RT, Wactawski-Wende J,  
Fridtjof Thomas EK, Anderson ML,  
et al. Menopausal hormone therapy and 
risks of melanoma and nonmelanoma 
skin cancers: Women’s health 
initiative randaomized trials. Journal 
of the National Cancer Institute. 
2011;103(19):1469-1475
[30] Ghosh R, Ott AM, Seetharam D, 
Slaga TJ, Kumar AP. Cell cycle block 
and apoptosis induction in a human 
melanoma cell line following treatment 
with 2-methoxyostradiol: Therapeutic 
implications? Melanoma Research. 
2003;13(2):119-127
[31] Kanda N, Watanbe S. 
17-β-estradiol, progesterone and 
dihydrotestosterone suppress the 
growth of human melanoma by 
inhibiting interleukin-8 production. 
The Journal of Investigative 
Dermatology. 2001;117:274-283
[32] Lipkin G. Sex factors in growth of 
malignant melanoma in hamsters: In 
vivo and in vitro correlation. Cancer 
Research. 1970;30:1928-1930
[33] Disorbo DM, McNulty B, 
Nathanson L. In vitro growth inhibition 
of human malignant melanoma cells 
by glucocorticoids. Cancer Research. 
1983;43:2664-2667
[34] Cos S, Garcia-Bolado A, Sanchez-
Barcelo E. Direct antiproliferative 
effects of melatonin on two metastatic 
Cutaneous Melanoma
10
cell sub-lines of mouse melanoma 
(B16BL6 and PG19). Melanoma 
Research. 2001;11(2):197-201
[35] Ramaraj P, Cox JL. In vitro effect 
of sex steroids on mouse melanoma 
(B16F10) cell growth. CellBio. 2014;3: 
60-71. DOI: 10.4236/cellbio.2014.32007
[36] Ramaraj P, Cox JL. In vitro effect 
of progesterone on human melanoma 
(BLM) cell growth. International 
Journal of Clinical and Experimental 
Medicine. 2014;7(11):3941-3953, PMID: 
25550902; PMCID: PMC4276160
[37] Seglen PO, Gordon PB. 
3-Methyladenine: Specific inhibitor 
of autophagic/lysosomal protein 
degradation in isolated rat hepatocytes. 
Proceedings of the National Academy 
of Sciences of the United States of 
America. 1982;79:1889-1892
[38] Jagannath C, Lindsey DR, 
Dhandayuthapani S, Xu Y, Hunter 
RL Jr, Eissa NT. Autophagy enhances 
the efficacy of BCG vaccine by 
increasing peptide presentation in 
mouse dendritic cells. Nature Medicine. 
2009;15(3):267-276
[39] Leder DC, Brown JR, Ramaraj P.  
In vitro rescue and recovery studies 
of human melanoma (BLM) cell 
growth, adhesion and migration 
functions after treatment with 
progesterone. International Journal of 
Clinical and Experimental Medicine. 
2015;8(8):12275-12285. PMID: 26550137 
[PubMed] PMCID: PMC4612822
[40] Fang X, Zhang X, Zhou M, Li J.  
Effects of progesterone on the growth 
regulation in classical progesterone 
receptor-negative malignant melanoma 
cells. Journal of Huazhong University 
of Science and Technology. Medical 
Sciences. 2010;30(2):231-234. DOI: 
10.1007/s 11596-010-0220-3
[41] Moroni G, Gaziano R, 
Bue C, Agostini M, Perno CF, 
Sinibaldi-Vallebona P, et al. 
Progesterone and melanoma cells: 
An old story suspended between life 
and death. Journal of Steroids and 
Hormonal Science. 2015;S13:158. DOI: 
10.4172/2157-7536.1000158
[42] Miller A, Fulcher A, Dock P, 
Ramaraj P. Biochemical basis of 
protection by progesterone in melanoma 
based on curcumin pre-treatment 
of human melanoma cell models. In: 
Endo2018Home; 2018. Available from: 
http://www.abstractsonline.com/
pp8/#!/4482/presentation/7469
[43] Schadendorf D, Möller A, 
Algermissen B, Worm M, Sticherling M,  
Czarnetzki BM. IL-8 produced by 
human malignant melanoma cells 
in vitro is an essential autocrine 
growth factor. Journal of Immunology. 
1993;151(5):2667-2675
[44] Luca M, Huang S, Gershenwald JE, 
Singh RK, Reich R, Bar-Eli M.  
Expression of interleukin-8 by human 
melanoma cells up-regulates MMP-2 
activity and increases tumor growth and 
metastasis. The American Journal of 
Pathology. 1997;151(4):1105-1113
[45] Singh RK, Gutman M, Radinsky R,  
Bucana CD, Fidler IJ. Expression 
of interleukin 8 correlates with 
the metastatic potential of human 
melanoma cells in nude mice. Cancer 
Research. 1994;54(12):3242-3247
[46] Häggström M. Reference ranges 
for estradiol, progesterone, luteinizing 
hormone and follicle-stimulating 
hormone during the menstrual cycle. 
WikiJournal of Medicine. 2014;1(1):1. 
DOI: 10.15347/wjm/2014.001
